{"product_id":"global-chronic-disease-management-therapeutics-and-device-technologies-market-size-study-forecast-by-disease-cardiovascular-diseases-cvd-diabetes-cancer-chronic-respiratory-diseases-chronic-kidney-diseases-neurological-disorders-others-such-a","title":"Global Chronic Disease Management Therapeutics and Device Technologies Market Size study \u0026 Forecast, by Disease (Cardiovascular diseases (CVD), Diabetes, Cancer, Chronic respiratory diseases, Chronic kidney diseases, Neurological disorders, Others (such a","description":"\u003cp\u003eGlobal Chronic Disease Management Therapeutics and Device Technologies Market Size study \u0026amp; Forecast, by Disease (Cardiovascular diseases (CVD), Diabetes, Cancer, Chronic respiratory diseases, Chronic kidney diseases, Neurological disorders, Others (such as autoimmune diseases, gastrointestinal disorders, and many)) by Therapy (Medications, Rehabilitation therapy, Behavioral therapy, Others (such as gene therapy, stem cell therapy, and many)), by Device (Blood glucose monitoring devices, Blood pressure monitors, Cardiac monitors, Respiratory therapy devices, Kidney dialysis machines, Neurostimulation devices, Others (such as insulin pumps, continuous glucose monitoring devices, and many)) and Regional Analysis, 2023-2030\u003cbr\u003e\nGlobal Chronic Disease Management Therapeutics and Device Technologies Market is valued at approximately USD 20.35 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 1.5% over the forecast period 2023-2030. The global chronic disease management therapeutics and device technologies market can be defined as the market for products and services that are used in the treatment and management of chronic diseases, such as diabetes, cardiovascular disease, cancer, respiratory disease, and others. This includes pharmaceuticals, medical devices, and other healthcare technologies that are designed to improve patient outcomes and quality of life by managing the symptoms and complications associated with chronic diseases. The driving factors for the Global Chronic Disease Management Therapeutics and Device Technologies Market are the growing prevalence of chronic diseases, growing geriatric population and rising healthcare expenditure. Moreover, increasing demand for innovative therapies and advances in medical technology is creating lucrative growth opportunities for the market over the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eThe Global Burden of Disease study estimated that in 2020, 1.7 billion people worldwide had at least one chronic disease, and 415 million had multiple chronic diseases. The global burden of chronic diseases is increasing, with conditions such as diabetes, cardiovascular disease, cancer, and respiratory disease affecting a growing number of people worldwide. This is driving demand for new and effective treatments and management strategies. For instance, in 2021, the International Diabetes Federation (IDF) reported that the global prevalence of diabetes had risen to 10.5% among adults, up from 9.3% in 2019. This represents an estimated 463 million adults living with diabetes worldwide. Similarly, according to the American Cancer Society, the global cancer burden is expected to rise to 29.5 million new cases annually by 2040, up from an estimated 19.3 million new cases in 2020. This represents an increase of more than 50% in just 20 years. However, the high cost of Chronic Disease Management Therapeutics and Device Technologies stifles market growth throughout the forecast period of 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Chronic Disease Management Therapeutics and Device Technologies Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East \u0026amp; Africa. North America is the dominating market for chronic disease management therapeutics and device technologies, accounting for a significant share of the global market. The region's strong healthcare infrastructure, high healthcare spending, and favorable reimbursement policies are driving the market growth. The Asia Pacific region is the fastest growing region in the chronic disease management therapeutics and device technologies market in the coming years. Factors driving market growth include the growing population, rising healthcare spending, and increasing prevalence of chronic diseases.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nMedtronic plc\u003cbr\u003e\nNovo Nordisk A\/S\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nF. Hoffmann-La Roche Ltd\u003cbr\u003e\nGlaxoSmithKline plc\u003cbr\u003e\nJohnson \u0026amp; Johnson Consumer Inc.\u003cbr\u003e\nSanofi S.A.\u003cbr\u003e\nDexcom, Inc.\u003cbr\u003e\nAstraZeneca plc\u003cbr\u003e\nBecton, Dickinson and Company (BD)\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\n? In September 2020, Medtronic launched its MiniMed 770G insulin pump system, which uses advanced algorithms to automatically adjust insulin delivery to help people with diabetes better manage their blood sugar levels.\u003cbr\u003e\n? In June 2020, Abbott received FDA clearance for its FreeStyle Libre 2 continuous glucose monitoring system, which allows people with diabetes to monitor their glucose levels without the need for fingerstick.\u003cbr\u003e\nGlobal Chronic Disease Management Therapeutics and Device Technologies Market Report Scope:\u003cbr\u003e\n?Historical Data – 2020 - 2021\u003cbr\u003e\n?Base Year for Estimation – 2022\u003cbr\u003e\n?Forecast period - 2023-2030\u003cbr\u003e\n?Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\n?Segments Covered - Disease, Therapy, Device, Region\u003cbr\u003e\n?Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Disease offerings of key players.\u003c\/p\u003e\n\n\u003cp\u003eThe detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Disease:\u003cbr\u003e\nCardiovascular diseases (CVD)\u003cbr\u003e\nDiabetes\u003cbr\u003e\nCancer\u003cbr\u003e\nChronic respiratory diseases\u003cbr\u003e\nChronic kidney diseases\u003cbr\u003e\nNeurological disorders\u003cbr\u003e\nOthers (such as autoimmune diseases, gastrointestinal disorders, and many)\u003cbr\u003e\nBy Therapy:\u003cbr\u003e\nMedications\u003cbr\u003e\nRehabilitation therapy\u003cbr\u003e\nBehavioral therapy\u003cbr\u003e\nOthers (such as gene therapy, stem cell therapy, and many)\u003cbr\u003e\nBy Device:\u003cbr\u003e\nBlood glucose monitoring devices\u003cbr\u003e\nBlood pressure monitors\u003cbr\u003e\nCardiac monitors\u003cbr\u003e\nRespiratory therapy devices\u003cbr\u003e\nKidney dialysis machines\u003cbr\u003e\nNeurostimulation devices\u003cbr\u003e\nOthers (such as insulin pumps, continuous glucose monitoring devices, and many)\u003c\/p\u003e\n\n\u003cp\u003eBy Region:\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003c\/p\u003e\n\n\u003cp\u003eLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003cbr\u003e\nSaudi Arabia\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nRest of Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003c\/p\u003e\n\n\u003cp\u003eMedtronic plc\u003cbr\u003e\nNovo Nordisk A\/S\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nF. Hoffmann-La Roche Ltd\u003cbr\u003e\nGlaxoSmithKline plc\u003cbr\u003e\nJohnson \u0026amp; Johnson Consumer Inc.\u003cbr\u003e\nSanofi S.A.\u003cbr\u003e\nDexcom, Inc. \u003cbr\u003e\nAstraZeneca plc\u003cbr\u003e\nBecton, Dickinson and Company (BD)\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 200 Pages \/ MCW16230083","offer_id":47647039553842,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-chronic-disease-management-therapeutics-and-device-technologies-market-size-study-forecast-by-disease-cardiovascular-diseases-cvd-diabetes-cancer-chronic-respiratory-diseases-chronic-kidney-diseases-neurological-disorders-others-such-a","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}